Martin Bookman
Keine laufenden Positionen mehr
Profil
Martin Bookman was an Acting Chief Financial Officer of Advanced Viral Research Corp.
from April 2004 to March 25, 2009.
Previously, he was Assistant Controller of Advanced Viral Research from March 2001 to April 2004.
From August 2000 to March 2001, Mr. Bookman was a Senior Consultant for Prodigy Communications, Inc. From August 1997 to August 2000, he was Manager of Policies and Procedures and Assistant Controller for Murray Feiss Import Corp.
Ehemalige bekannte Positionen von Martin Bookman
| Unternehmen | Position | Ende |
|---|---|---|
Advanced Viral Research Corp.
 Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Finanzdirektor/CFO | 26.03.2009 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
